Overview

Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The study aims to compare between two bolus doses of dexmedetomidine in preventing PONV in highly susceptible patients.
Phase:
N/A
Details
Lead Sponsor:
Cairo University
Treatments:
Dexmedetomidine